Low prevalence of Post-thrombotic syndrome in patients treated with rivaroxaban

Ferreira, Tatiane; Huber, Stephany Cares; Martinelli, Beatriz de Moraes; Lemos, Arlindo Nascimento de; Menezes, Fábio Hüsemann; Orsi, Fernanda Andrade; Bittar, Luis Fernando; Oliveira, Luiz Frederico Gerbase de; Sodre, Leonardo Ragazzi; Mello, Tayana Teixeira; Rielli, Glauber; Colella, Marina Pereira; Paula, Erich Vinícius De; Yamaguti-Hayakawa, Gabriela G; Montalvão, Silmara Aparecida de Lima; Annichino‐Bizzacchi, Joyce Maria

doi:10.1016/j.vph.2019.106608

Cited by 22 publications

(29 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a clinic, the treatments for DVT patients including anticoagulation and surgical intervention are always ineffective. Many DVT patients suffered from postthrombotic syndrome, major bleeding, and even death [4,5]. Thus, it is essential to study the molecular mechanism of DVT and explore alternative therapies for DVT treatment.…”

Section: Introductionmentioning

confidence: 99%

Overexpression of MicroRNA-122 Resists Oxidative Stress-Induced Human Umbilical Vascular Endothelial Cell Injury by Inhibition of p53

Pan

Yang

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Deep venous thrombosis (DVT) constitutes a great threat to health worldwide. Endothelial cell injury and dysfunction comprise the critical contributor for the development of DVT. However, the mechanism behind it remains poorly elucidated. The study is aimed at investigating the role of microRNA-122 (miR-122) and oxidative stress on DVT. The results showed that miR-122 overexpression dampened H2O2-evoked cytotoxic injury in human umbilical vein endothelial cells (HUVECs) by increasing cell viability, suppressing cell apoptosis and oxidative stress injury. Notably, miR-122 overexpression attenuated provasoconstriction factor endothelin-1 (ET-1) expression in HUVECs exposed to H2O2 but enhanced the productions of vasodilatation factor Prostaglandin F1α (PGF1α). Moreover, inhibition of miR-122 had the opposite results. miR-122 could inhibit the expression of p53. Low expression of p53 could enhance the protection of miR-122 on HUVEC injury. This study highlights that miR-122 overexpression may restore H2O2-induced HUVEC injury by regulating the expression of p53.

show abstract

Section: Introductionmentioning

confidence: 99%

Overexpression of MicroRNA-122 Resists Oxidative Stress-Induced Human Umbilical Vascular Endothelial Cell Injury by Inhibition of p53

Pan

Yang

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…In a prospective, randomized single‐center study from Brazil, 84 patients were assessed for PTS 12 months after DVT and there was a statistically significant lower prevalence of PTS in patients treated with rivaroxaban compared to those treated with warfarin (8.7% versus 28.9%, respectively, P < .01) 22 . Another retrospective multicenter study from Brazil also concluded with a possible benefit of rivaroxaban over warfarin after 15 months among 127 patients with DVT (50.7% vs. 69%, P = .002) 23 . Prandoni et al recently published a study comparing the prevalence of PTS at 3 years in a prospective cohort of 309 patients treated with rivaroxaban, apixaban, or dabigatran, compared to a historical cohort of 1036 patients treated with warfarin 25 .…”

Section: Discussionmentioning

confidence: 96%

Post‐thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long‐term cross‐sectional follow‐up of RE‐COVER study patients

Wik

Kahn

Eriksson

et al. 2021

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

Background Studies suggest that the direct factor Xa inhibitor rivaroxaban compared to warfarin reduces the risk of post‐thrombotic syndrome (PTS) after deep vein thrombosis (DVT), but this has not been evaluated for oral direct thrombin inhibitors. Objectives To compare the long‐term prevalence of PTS, recurrent venous thromboembolism (VTE), and health‐related quality of life (HRQoL) in patients with acute DVT and/or pulmonary embolism (PE), randomized to treatment with dabigatran or warfarin in the phase III RE‐COVER studies. Methods We conducted a cross‐sectional follow‐up study of patients randomized in Canada, Norway, and Sweden. PTS was assessed by the patient‐reported Villalta scale (PRV) and HRQoL by EQ‐5D and VEINES‐QOL/Sym. Results We included 349 patients between December 2015 and November 2018; 166 were treated with dabigatran and 183 with warfarin. DVT (+/− PE) was index event in 255 patients, whereas 94 patients had PE only. Mean time from index event was 8.7 (standard deviation 1.4) years. PTS was diagnosed in 63% of patients with DVT and in 46% of patients with PE only, and did not differ between the treatment groups; the crude odds ratio (OR) for PTS in patients treated with dabigatran compared with warfarin was 1.1 (95% confidence interval [CI] 0.6–1.8) after DVT and 1.2 (95% CI 0.5–2.6) after PE only. The prevalence of recurrent VTE was 21% in both treatment groups. HRQoL scores did not differ between groups. Conclusion In this long‐term cross‐sectional study, the prevalence of PTS, recurrent VTE, and HRQoL were similar in patients treated with dabigatran and warfarin.

show abstract

“…131,132 With PTS speculated to be secondary to ineffective clot resolution, it has been postulated that DOACs may improve rates of PTS compared with warfarin. Several retrospective analyses and a post hoc analysis of the EINSTEIN DVT trial have suggested that DOACs may reduce rates of PTS compared with warfarin, [133][134][135][136][137] and a pilot study evaluating rivaroxaban compared with LMWH is ongoing. 138…”

Section: Targeting Leukocyte Recruitmentmentioning

confidence: 99%

Advances in the Management of Acute Venous Thromboembolism and New Therapeutic Agents

Stevens

McFadyen

Chan

2021

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Important advances in the understanding and management of venous thromboembolism (VTE) have enhanced our ability to diagnose, prevent, and treat VTE. In this narrative review, we discuss how recent advances in the understanding and management of VTE are changing practice, highlight ongoing unmet needs in VTE management, and outline how novel therapeutic targets with little or no influence on hemostasis may help address these unmet needs.

show abstract

Low prevalence of Post-thrombotic syndrome in patients treated with rivaroxaban

Cited by 22 publications

References 23 publications

Overexpression of MicroRNA-122 Resists Oxidative Stress-Induced Human Umbilical Vascular Endothelial Cell Injury by Inhibition of p53

Overexpression of MicroRNA-122 Resists Oxidative Stress-Induced Human Umbilical Vascular Endothelial Cell Injury by Inhibition of p53

Post‐thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long‐term cross‐sectional follow‐up of RE‐COVER study patients

Advances in the Management of Acute Venous Thromboembolism and New Therapeutic Agents

Contact Info

Product

Resources

About